Atea Pharmaceuticals, Inc. is a US-based pharmaceutical company specializing in antiviral therapeutics. With a high-risk ESG score of 36.1, the company is focused on developing treatments for serious viral infections such as COVID-19 and Hepatitis C. Atea Pharmaceuticals is dedicated to improving the lives of patients through the discovery and commercialization of innovative medications.